Intercept Pharma (ICPT) Tops Q3 EPS by 49c

Intercept Pharma (NASDAQ: ICPT) reported Q3 EPS of ($2.89), $0.49 better than the analyst estimate of ($3.38). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $37.01 million.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Evogene (EVGN) Tops Q2 EPS by 15c